Observational studyAge and ageing2026
Life expectancy estimation in older men using the prostate cancer comorbidity index in VA & SEER-Medicare cohorts.
Observational study in Age and ageing, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGuidelines endorse specific life expectancy (LE) cutoffs for triage of definitive local treatment of prostate cancer, but the lack of validated, prostate cancer-specific LE prediction tools limits incorporation of LE in management decisions.
objectiveWe sought to provide long-term LE predictions in older men using the Prostate Cancer Comorbidity Index (PCCI), a validated tool for prediction of other-cause mortality based on age and presence and severity of major comorbidities, in nationally representative cohorts of US prostate cancer patients. DESIGN, SETTING, SUBJECTS: We performed an observational study of 916,890 men in the SEER-Medicare database and 243,928 men in the VA diagnosed with clinically localized prostate cancer between 2000 and 2019.
methodsPCCI scores were calculated using ICD-9 and ICD-10 codes. Kaplan Meier and multivariable Cox proportional hazards analysis were used to measure overall survival by age-adjusted PCCI score groups.
resultsMedian follow up was 11 years in both cohorts. In SEER-Medicare, men with PCCI scores of 1-2, 3-4, 5-6, 7-9, and 10+ had median estimated LE (95%CI) of 16.6 (16.5-16.7), 12.2 (12.1-12.2), 10.7 (10.6-10.7), 9.3 (9.2-9.3), and 5.4 (5.3-5.4) years, respectively. In the VA, men with the same PCCI scores had estimated median LE (95%CI) of 16.1 (16.0-16.3), 11.2 (11.1-11.4), 9.1 (8.9-9.2), 7.5 (7.4-7.7), and 5.2 (5.0-5.3) years, respectively.
conclusionsThe PCCI robustly predicts long-term longevity in SEER-Medicare and VA populations, with similar LE estimates in each. LE prediction tables with their accompanying variability estimates can help clinicians implement guidelines endorsed LE cutoffs for management of older men with prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.